Holmevis

Active Ingredient:: Ibandronate Sodium Hydrate
Origin:: EU

Holmevis (Ibandronate Sodium Hydrate)

Q: What is the active ingredient in Holmevis and how is it administered?

Holmevis contains ibandronate sodium hydrate as its active ingredient and is administered as an intravenous solution by a healthcare professional.

Q: For which types of osteoporosis is Holmevis prescribed?

Holmevis is prescribed for postmenopausal osteoporosis and for osteoporosis that results from long‑term glucocorticoid therapy.

Q: How does ibandronate reduce bone loss?

Ibandronate binds to bone mineral, is taken up by osteoclasts, and inhibits an enzyme in the mevalonate pathway, leading to osteoclast apoptosis and decreased bone resorption.

Q: What are the most common side effects after an ibandronate IV infusion?

Common side effects include flu‑like symptoms such as fever and chills, transient muscle or joint pain, mild nausea, headache, and local reactions at the injection site.

Q: When should Holmevis be avoided because of kidney concerns?

Holmevis should be avoided in patients with severe renal impairment, typically defined as a creatinine clearance below 30 mL/min, due to the risk of further kidney injury.

Q: Do calcium supplements interfere with Holmevis treatment?

Calcium or magnesium supplements taken within four hours of the infusion can reduce ibandronate absorption and should be avoided during that time window.

Q: Is Holmevis safe to use during pregnancy?

The safety of Holmevis in pregnancy has not been established; it should be used only if the potential benefit justifies the potential risk to the fetus.

Q: What monitoring is recommended while a patient receives Holmevis?

Renal function, serum calcium levels, and vitamin D status should be monitored before and during treatment with Holmevis.

Q: Can Holmevis be given to patients who have had jaw surgery?

Patients with a history of jaw surgery or dental disease should be evaluated carefully, as ibandronate is associated with a risk of osteonecrosis of the jaw.

Q: How often is Holmevis typically administered?

The dosing interval for ibandronate IV formulations varies; clinicians determine the schedule based on the specific product labeling and patient needs.

Holmevis is an intravenous solution containing the active ingredient ibandronate sodium hydrate. It is a prescription bisphosphonate used in the European market for the treatment of osteoporosis. The product is administered by healthcare professionals and is classified under ATC code M05BA07. Holmevis works by targeting bone metabolism to reduce the risk of fractures in patients with low bone density.

Manufacturer / TM Owner

Egis Pharmaceuticals Plc

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Holmevis is indicated for the management of osteoporosis in specific patient groups. It is prescribed to help maintain bone strength and reduce fracture risk.

Treatment of postmenopausal osteoporosis
Prevention of glucocorticoid‑induced osteoporosis
Long‑term management of established osteoporosis
Adjunct therapy for patients at high risk of vertebral fractures
Use in patients who cannot tolerate oral bisphosphonates

How It Works

Ibandronate sodium hydrate binds selectively to hydroxyapatite crystals on bone surfaces, especially at sites of active remodeling. Once attached, it is internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, leading to impaired prenylation of small GTP‑binding proteins. This disruption triggers osteoclast apoptosis and reduces bone resorption, thereby helping to preserve bone mass and strength.

Side Effects

Adverse reactions to Holmevis can vary in frequency and severity.

Common

Flu-like symptoms (fever, chills, myalgia)
Transient musculoskeletal pain
Nausea or mild gastrointestinal discomfort
Headache
Injection site reactions such as erythema or swelling

Serious

Acute phase reaction with high fever
Severe renal impairment or acute kidney injury
Hypocalcemia leading to tetany or seizures
Atypical femoral fractures
Osteonecrosis of the jaw

Precautions & Warnings

Before initiating Holmevis, certain safety considerations should be reviewed.

Assess renal function; avoid use in severe renal impairment (creatinine clearance <30 mL/min)
Correct calcium and vitamin D deficiencies prior to treatment
Monitor serum calcium levels during therapy
Use with caution in patients with a history of esophageal disorders
Evaluate for prior or current jaw pathology before administration
Discontinue if acute inflammatory reactions develop after infusion
Discuss pregnancy and lactation status; safety data are limited

Avoid Interactions

Holmevis may interact with other medications, requiring attention to avoid reduced efficacy or increased toxicity.

Avoid

Concomitant use of other bisphosphonates or potent nephrotoxic agents (e.g., aminoglycosides, NSAIDs)
High-dose calcium or magnesium supplements taken within 4 hours of infusion

Use with caution

Loop diuretics that may affect calcium balance
Antacids containing aluminum or magnesium if administered close to the infusion time
Corticosteroids that increase osteoporosis risk
Vitamin D analogues that may alter calcium homeostasis
Drugs affecting renal function such as ACE inhibitors or ARBs

Frequently Asked Questions

Holmevis contains ibandronate sodium hydrate as its active ingredient and is administered as an intravenous solution by a healthcare professional.

Holmevis is prescribed for postmenopausal osteoporosis and for osteoporosis that results from long‑term glucocorticoid therapy.

Ibandronate binds to bone mineral, is taken up by osteoclasts, and inhibits an enzyme in the mevalonate pathway, leading to osteoclast apoptosis and decreased bone resorption.

Common side effects include flu‑like symptoms such as fever and chills, transient muscle or joint pain, mild nausea, headache, and local reactions at the injection site.

Holmevis should be avoided in patients with severe renal impairment, typically defined as a creatinine clearance below 30 mL/min, due to the risk of further kidney injury.

Calcium or magnesium supplements taken within four hours of the infusion can reduce ibandronate absorption and should be avoided during that time window.

The safety of Holmevis in pregnancy has not been established; it should be used only if the potential benefit justifies the potential risk to the fetus.

Renal function, serum calcium levels, and vitamin D status should be monitored before and during treatment with Holmevis.

Patients with a history of jaw surgery or dental disease should be evaluated carefully, as ibandronate is associated with a risk of osteonecrosis of the jaw.

The dosing interval for ibandronate IV formulations varies; clinicians determine the schedule based on the specific product labeling and patient needs.

Patients should contact their healthcare provider promptly; severe fever, chills, or other acute symptoms may require medical evaluation and possible discontinuation of therapy.

Concurrent use of other bisphosphonates, potent nephrotoxic drugs, and high‑dose calcium or magnesium supplements near the infusion time should be avoided.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 23 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.